Cost-effectiveness analysis of infliximab versus CinnoRA in the treatment of moderate to severe ulcerative colitis in Iranian patients

Olfatifar, M.; Asadzadeh Aghdaei, H.; Hasanpour Dehkordi, A.; Shahrokh, S.; Pourhoseingholi, M.A.; Balaii, H.; Mohsen Rajabnia, M.; Ivanchuk, Maria; Ivanchuk, Pavlo; Hashemi Nazari, S.; Sabour, S.; Rohani, P.; Mehralian, G.; Khodakarim, S.; Hatami, B.; Malekpour, H.; Sherkat, G.; Zali, M.R.; Rahimi Pordanjani, S.

Cost-effectiveness analysis of infliximab versus CinnoRA in the treatment of moderate to severe ulcerative colitis in Iranian patients

Olfatifar, M.; Asadzadeh Aghdaei, H.; Hasanpour Dehkordi, A.; Shahrokh, S.; Pourhoseingholi, M.A.; Balaii, H.; Mohsen Rajabnia, M.; Ivanchuk, Maria; Ivanchuk, Pavlo; Hashemi Nazari, S.; Sabour, S.; Rohani, P.; Mehralian, G.; Khodakarim, S.; Hatami, B.; Malekpour, H.; Sherkat, G.; Zali, M.R.; Rahimi Pordanjani, S.

URI: http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/26160

Date: 2023

Abstract:

Objectives: This study was done to evaluate the cost-effectiveness of IFX versus CinnoRA for the treatment of moderate-to-severe UC patients. Conclusion: Our results demonstrated that IFX is more effective and more costly than CinnoRA, and if we ignore the predicted surgeries, CinnoRA is nearly as effective as IFX. However, these ﬁndings should be cautiously interpreted without a robust clinical trial of CinnoRA in UC patients. Since the impact of CinnoRA may have been over/underestimated.

Show full item record